Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm

Cancer Cell(2020)10.1016/j.ccell.2020.10.021Source: DataRank Database

The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm is a research paper published in Cancer Cell (2020). On theSindex it has a DataRank of 0. It has been cited 38 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access38 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 2.41)OA: bronzeTopics (43)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Satwik Rajaram ORCID,Alana Christie ORCID,Payal Kapur ORCID,James Brugarolas ORCID

Live enrichment

PubMed:33157049 PMC:PMC9807219 OpenAlex:https://openalex.org/W3096093146

Cancer Prevention and Research Institute of Texas

Grant: R01CA154475

Cancer Prevention and Research Institute of Texas

Grant: R01DK115986

Cancer Prevention and Research Institute of Texas

Grant: R01CA244579

Cancer Prevention and Research Institute of Texas

Grant: RP180192

Cancer Prevention and Research Institute of Texas

Grant: RP180191

National Institutes of Health

Grant: P50 CA196516

U.S. Department of Defense

Grant: W81XWH1910710

U.S. Department of Defense

Grant: RP200233

Exelixis

Grant: 15/761,534

National Institutes of Health

U.S. Department of Defense

Cancer Prevention and Research Institute of Texas

FWCI

2.41

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S1535610820305523/pdf

publisherhttp://www.cell.com/article/S1535610820305523/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610820305523?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610820305523?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2020.10.021

Fields of Study

Renal cell carcinoma treatmentCancer Genomics and DiagnosticsRenal and related cancersAngiogenesis InhibitorsAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellClinical Trials as TopicEvolution, MolecularGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKidney NeoplasmsMutation

MeSH Terms

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsCarcinoma, Renal CellClinical Trials as TopicHumansKidney NeoplasmsMutationBiomarkers, TumorGene Expression Regulation, NeoplasticEvolution, MolecularAngiogenesis InhibitorsGene Regulatory Networks

Keywords

BiologyRenal cell carcinomaGeneCancer researchCladeRenal carcinomaCancerAngiogenesisComputational biologyCarcinomaGeneticsPhylogeneticsPathologyMedicine

Sustainable Development Goals

SDG 0: Good health and well-being